{
    "clinical_study": {
        "@rank": "38712", 
        "brief_summary": {
            "textblock": "This study will compare the safety and effectiveness of two anti-HIV drug combinations in\n      fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with\n      other anti-HIV drug treatments."
        }, 
        "brief_title": "A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients experiencing virologic failure while receiving an IDV-containing antiretroviral\n      regimen will receive the 3TC/ABC/APV/NFV combination. Patients experiencing virologic\n      failure while receiving an NFV-containing antiretroviral regimen will receive the\n      3TC/ABC/APV/IDV combination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this trial if you:\n\n          -  Are HIV-positive.\n\n          -  Are 13 years of age or older.\n\n          -  Are currently taking anti-HIV drugs, 1 of which must be NFV or IDV, and have taken\n             these same drugs for at least 12 weeks.\n\n          -  In the last 16 weeks your viral load (level of HIV in the blood) dropped below 400\n             copies/ml and has since increased to at least 1,000 copies/ml, even though you\n             continue to take your anti-HIV drugs.\n\n          -  Have the written consent of a parent or legal guardian if you are under age 18.\n\n          -  Agree to practice abstinence or use effective barrier methods of birth control\n             (unless you are physically incapable of becoming pregnant).\n\n          -  Are willing to complete the 48-week study.\n\n        Exclusion Criteria\n\n        You will not be eligible for this trial if you:\n\n          -  Have ever taken the following anti-HIV drugs: ABC, APV, efavirenz (EFV), delavirdine\n             (DLV), nevirapine (NVP), or loviride.\n\n          -  Have certain AIDS-related infections or diseases, have other serious medical\n             conditions such as diabetes and certain types of heart trouble, or have a history of\n             lymphoma.\n\n          -  Have had certain types of hepatitis in the past 6 months.\n\n          -  Have received an HIV vaccine in the past 3 months or a flu vaccine in the past 30\n             days.\n\n          -  Have certain digestion problems that make it difficult to take anti-HIV drugs by\n             mouth.\n\n          -  Have received certain other drugs or treatments in the past 30 days, or will need\n             certain drugs or treatments during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002423", 
            "org_study_id": "264M", 
            "secondary_id": "PRO20005"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Nelfinavir", 
                "Amprenavir", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Abacavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "Indinavir", 
            "Nelfinavir", 
            "VX 478", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "Saint Francis Mem Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altamonte Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32701"
                    }, 
                    "name": "IDC Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Natl Institute of Allergy and Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Kansas City AIDS Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Bentley-Salick Med Practice"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "74114"
                    }, 
                    "name": "Associates in Med and Mental Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "972109951"
                    }, 
                    "name": "Portland Veterans Adm Med Ctr / Rsch & Education Grp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg BID) Plus Either Nelfinavir (1250 Mg BID) or Indinavir (800 Mg TID) for 48 Weeks", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002423"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 1999", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1999"
    }, 
    "geocoordinates": {
        "Associates in Med and Mental Health": "36.154 -95.993", 
        "Bentley-Salick Med Practice": "40.714 -74.006", 
        "Georgetown Univ Med Ctr": "38.895 -77.036", 
        "IDC Research Initiative": "28.661 -81.366", 
        "Kansas City AIDS Research Consortium": "39.1 -94.579", 
        "Natl Institute of Allergy and Infectious Diseases": "38.985 -77.095", 
        "Portland Veterans Adm Med Ctr / Rsch & Education Grp": "45.523 -122.676", 
        "Saint Francis Mem Hosp": "37.775 -122.419"
    }
}